CHD Chemicals reported a net loss of Rs 31.36 lakhs for FY26 compared to Rs 19.64 lakhs previously. The board has proposed increasing authorized share capital to Rs 36 crore and diversifying into agro-based products. Investors should note an adverse audit opinion regarding accounting framework compliance.
CHD Chemicals Financial Update and Strategic Expansion
Net loss widened to Rs 31.36 lakhs in FY 2025-26 from Rs 19.64 lakhs in FY 2024-25.
Authorized share capital increase proposed from Rs 11 crore to Rs 36 crore.
Reader Takeaway: Expansion plans and capital infusion signal growth intent, but accounting compliance issues and recurring losses pose risks.
What just happened
CHD Chemicals Ltd announced its financial results for the fiscal year ended 2026, revealing a decline in profitability. Alongside the earnings report, the company announced significant board-led strategic proposals. These include a major hike in authorized share capital and a move to diversify the firm's business into food and agricultural sectors.
Why this matters
The company received an adverse audit opinion from Gams & Associates LLP. The auditors flagged that CHD Chemicals failed to adopt the mandatory Indian Accounting Standards (Ind AS), instead using outdated standards. This raises transparency concerns for shareholders. Additionally, the company faces scrutiny over past compliance delays with SEBI regulations and ROC filings, for which a nominal penalty has already been settled.
What changes now
The board is seeking shareholder approval at the upcoming Annual General Meeting on September 30, 2026, for two critical resolutions. First, the increase in authorized share capital to Rs 36 crore suggests a potential for future fundraising or stock issuance. Second, the alteration of the Object Clause will allow the company to trade and manufacture agro-chemicals and food products, marking a shift from its core business operations.
Risks to watch
The primary risk is the company's financial health, as total income fell from Rs 688.45 lakhs to Rs 525.34 lakhs year-on-year. Investors should watch how management plans to address the audit non-compliance, as transitioning to Ind AS is a regulatory necessity. Furthermore, the effectiveness of the diversification strategy remains unproven against a backdrop of shrinking revenues.
What to track next
Shareholders should monitor the outcomes of the resolutions at the September 30 AGM. Tracking the company's transition to Ind AS in subsequent disclosures will be essential for assessing corporate governance standards moving forward.